Stocks have thus far avoided another big down day following yesterday’s collapse, but it still feels like there’s another shoe to drop, doesn’t it?
Getty Images
So how will we know that the worst is over? Fundstrat technical analyst Robert Sluymer recommends “watching the downside leader, Energy, for evidence of decelerating,” particularly ExxonMobil (XOM) and Chevron (CVX). He explains:
Beyond the obvious defensive relative rotation underway favoring Bond proxies, Staples and Restaurants at the expense of Cyclicals and Financials, we are monitoring Energy closely. Why? Energy, peaked in relative performance terms in December and has since led Cyclicals lower. While it is premature to suggest an improvement is developing for the sector, the list of names making new multi-week relative lows has not expanded during recent market weakness. Although XOM and CVX are the most defensive names in the sector, relative performance is showing early signs of improving, as both names become tactically. Defensive exposure with an offensive option?
stock market: Madison Square Garden Inc.(MSG)
Advisors’ Opinion:
- [By Monica Gerson]
Madison Square Garden Co (NYSE: MSG) is estimated to report a quarterly loss at $0.34 per share on revenue of $325.53 million.
Gogo Inc (NASDAQ: GOGO) is projected to report a quarterly loss at $0.42 per share on revenue of $137.58 million.
- [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]
Meanwhile, Mark Boyar, of The Boyar Value Fund, recommends another household name: Madison Square Garden (MSG). He thinks the Dolan family could take the company private.
stock market: Bayer Aktiengesellschaft (BAYRY)
Advisors’ Opinion:
- [By SEEKINGALPHA.COM]
You can torture the data many ways, of course, and there were some pharma price increases in the US, but apparently, they were not especially large. What hurt were discounting, especially for Xarelto, a Bayer (OTCPK:BAYRY) oral anticoagulant which JNJ markets in the US; and the diabetes Invokana line.
- [By SEEKINGALPHA.COM]
The Regeneron press release in November for its Q3 2017 financial and operating results reaffirmed Eylea’s full year 2017 U.S. net product sales growth of approximately 10% over 2016, which could be about $1 billion. From our model, we see the Q4 total revenues for Eylea, excluding sales outside the United States from Regeneron’s collaborative partner Bayer AG (OTCPK:BAYRY), of $1.2 billion, or a 17% increase year-on-year. REGN stock has a forward P/E ratio of 21.83 as of December 8, 2017, while the current trailing P/E is 34.57.
- [By Todd Campbell]
Nektar Therapeutics is working with Bayer AG (NASDAQOTH:BAYRY) on an inhaledversion of Amikacin, an anti-bacterial that if successful in trials could be used alongside standard of care to treat gram-negative pneumonia in intubated and mechanically ventilated patients. If it’s eventually approved in the U.S., Nektar Therapeutics will receive a flat 30% royalty on sales. It’s also working with Bayer on an inhaled powder formulation of Cipro that could be used to treat chronic lung infections in cystic fibrosis patients. Top-line phase 3 results on both drugs should be available this year.
- [By SEEKINGALPHA.COM]
This type of spin-off is not uncommon among German companies, as they streamline their portfolios to focus on the where they have more competitive advantages in the long term. For instance, in the recent past, Siemens (OTCPK:SIEGY) has split out Osram (OTC:OSAGY) and Bayer (OTCPK:BAYRY) has performed the spin-off of Covestro (OTCPK:CVXTY), something that Rheinmetall is likely to do in the near future because its auto unit has reached peak margins, and therefore this is the best time to spin-off the business.
- [By SEEKINGALPHA.COM]
Rivaroxaban was initially developed by Janssen, a subsidiary of Johnson & Johnson (NYSE:JNJ). It later entered an agreement with Bayer (OTCPK:BAYRY) to jointly complete the development process in 2005.
- [By SEEKINGALPHA.COM]
A very risky Phase 3 drug for high cholesterol, anacetrapib, is listed and is in Phase 3; but several others of the class have failed, and there’s little reason to expect a success here (but you never know). Finally, a partnered heart failure drug that is also in Phase 3, vericiguat, is partnered with Bayer (OTCPK:BAYRY). This compound failed its primary endpoint in Phase 2. Yet, the partners agreed that there was hope for the highest of the three doses. Thus, I view this drug as a very high risk Phase 3 product. Maybe it will be successful and blockbuster, but it’s no sure thing.
stock market: Conn's, Inc.(CONN)
Advisors’ Opinion:
- [By Peter Graham]
A long term performance chart shows shares of Best Buy Co outperforming potential peersactive in electronics retailing such asmid capAaron’s, Inc (NYSE: AAN)and small cap CONN’S, Inc (NASDAQ: CONN):
- [By Chris Lange]
Conn’s Inc. (NASDAQ: CONN) will share its latest quarterly earnings on Thursday. The consensus estimates call for a net loss of $0.07 per share and $413.12 million in revenue. Shares were at $6.84 on Fridays close, in a 52-week range of $6.54 to $34.60. The consensus price target is $13.17.
- [By Lisa Levin]
Conn's Inc (NASDAQ: CONN) shares were also up, gaining 32 percent to $11.18 after the company reported better-than-expected earnings for its fourth quarter.
- [By Monica Gerson]
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Monday’s regular session.
Pier 1 Imports Inc (NYSE: PIR) Dec16 5.0 Puts Sweep: 1191 @ ASK $0.80: 1354 traded vs 102 OI: $5.32 Ref
Alcoa Inc (NYSE: AA) Jul16 9.5 Puts Sweep: 1494 @ ASK $0.13: 14k traded vs 6682 OI: $10.09 Ref
Sarepta Therapeutics Inc (NASDAQ: SRPT) Jul16 10.0 Puts: 3536 @ ASK $0.50: 5506 traded vs 54k OI: Earnings 8/4 $22.50 Ref
Tableau Software Inc (NYSE: DATA) Jul16 47.5 Puts Sweep: 837 @ ASK $0.30: 995 traded vs 37 OI: Earnings 8/3 $50.60 Ref
Yandex NV (NASDAQ: YNDX) Aug16 18.0 Puts Sweep: 532 @ ASK $0.30: 2143 traded vs 78 OI: Earnings 7/28 Before Open $22.02 Ref
Wolverine World Wide, Inc. (NYSE: WWW) Aug16 22.5 Puts: 719 @ ASK $1.35: 1032 traded vs 0 OI: Earnings 7/19 $22.22 Ref
Conn's Inc (NASDAQ: CONN) Jan17 5.0 Puts Sweep: 605 @ ASK $0.85: 1355 traded vs 3132 OI: $7.16 Ref
Posted-In: Huge Put PurchasesNews Options Markets
- [By Lisa Levin]
Conn’s Inc (NASDAQ: CONN) shares dropped 23 percent to $9.03 as the company reported downbeat quarterly results. Conn’s posted a Q1 loss of $0.31 per share on revenue of $389.1 million.
- [By Lisa Levin]
Wednesday afternoon, the cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Conn's Inc (NASDAQ: CONN) and Wyndham Worldwide Corporation (NYSE: WYN).
stock market: Leading Brands Inc(LBIX)
Advisors’ Opinion:
- [By Lisa Levin]
Leading Brands, Inc (USA) (NASDAQ: LBIX) shares dropped 13 percent to $1.99 following Q2 results. Leading Brands posted Q2 EBITDAS of $0.00 per share, compared to $0.09 per share during the same period last year.
- [By Lisa Levin]
Leading Brands, Inc (USA) (NASDAQ: LBIX) shares shot up 66 percent to $2.49 following Q1 results. Leading Brands reported Q1 earnings of $0.10 per share on revenue of $3.033 million.
- [By Lisa Levin]
Leading Brands, Inc (USA) (NASDAQ: LBIX) shares were also up, gaining 145 percent to $3.31 on no formal news from company. The stock rallied 215 percent over Tuesday and Wednesday of this week amid trader speculation stock could be sympathy play on move higher in Helios & Matheson. However, Leading Brands shares sold off 27 percent on Thursday.
stock market: Telephone and Data Systems, Inc.(TDS)
Advisors’ Opinion:
- [By Monica Gerson]
Telephone & Data Systems, Inc. (NYSE: TDS) is projected to report its quarterly earnings at $0.10 per share on revenue of $1.26 billion.
PharMerica Corporation (NYSE: PMC) is estimated to report its quarterly earnings at $0.43 per share on revenue of $509.45 million.
